Healthcare plays an important role in the EU’s economy, accounting for 8% of the total workforce and for 10% of its GDP. As the EU bank, we support healthcare projects that aim to ensure universal access to high-quality and affordable services.
Good health is not only an essential component of our lives; it is also a precondition for the prosperity of our society. Increasing life expectancies produce demographic changes, which in turn affect public pension and healthcare schemes, as well as family and community services.
In collaboration with the European Commission, the EIB Group is using existing financial instruments like the InnovFin Infectious Disease Finance Facility to support projects that work towards halting the spread of, finding a cure for and developing a vaccine against COVID-19.
BioNTech and CureVac are two of the companies financed by the EIB to develop a COVID-19 vaccine, while Pluristem, Atriva Therapeutics and Immunic benefit from EIB backing to work on potential therapies. Scope Fluidics has received EIB support to continue their work on new, affordable methods to detect pathogens like SARS-CoV-2, the virus that causes COVID-19.
As part of the Team Europe effort, the Bank also supports the COVAX facility, whose goal is to accelerate the development and manufacture of COVID-19 vaccines and to guarantee fair and equitable access for every country in the world.
BioNTech advances towards COVID-19 vaccine with EIB backing
When Özlem Türeci and her husband, Uğur Şahin, announced that the COVID-19 vaccine developed by their company, BioNTech, had excellent results in its latest tests, the couple took a short break from their round-the-clock research schedule. But only long enough to drink a cup of tea.
Conscious of the vital nature of their research, the two immune engineers have led the Mainz-based company to the frontrunner’s spot in the race for a vaccine.
EU Malaria Fund: investment from the European Union, the EIB, Investitionsbank Berlin, the Bill & Melinda Gates Foundation, and other European national and private actors to support scientifically promising projects that aim to prevent and treat malaria